ENLIVEN THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $354.00K, a 17.10% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $427.00K, a 33.44% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $320.00K.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $620.00K, a 4.76% decline from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $651.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $354.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $620.00K 10-K · filed 2026-03-03 | |
| 2025-06-30 | $427.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $651.00K 10-K · filed 2026-03-03 | |
| 2024-06-30 | $320.00K 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |